These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16096817)

  • 41. Perception of coarticulatory information in normal speech and dysarthria.
    Tjaden K; Sussman J
    J Speech Lang Hear Res; 2006 Aug; 49(4):888-902. PubMed ID: 16908883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of clear speech intervention program on speech intelligibility in persons with idiopathic Parkinson's disease: A pilot study.
    Shin H; Shivabasappa P; Koul R
    Int J Speech Lang Pathol; 2022 Feb; 24(1):33-41. PubMed ID: 34229555
    [No Abstract]   [Full Text] [Related]  

  • 43. Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial.
    Constantinescu G; Theodoros D; Russell T; Ward E; Wilson S; Wootton R
    Int J Lang Commun Disord; 2011; 46(1):1-16. PubMed ID: 21281410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between acoustic measures and speech naturalness ratings in Parkinson's disease: A within-speaker approach.
    Klopfenstein M
    Clin Linguist Phon; 2015; 29(12):938-54. PubMed ID: 26403503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rate and loudness manipulations in dysarthria: acoustic and perceptual findings.
    Tjaden K; Wilding GE
    J Speech Lang Hear Res; 2004 Aug; 47(4):766-83. PubMed ID: 15324285
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accuracy and inter-observer variation in the classification of dysarthria from speech recordings.
    Fonville S; van der Worp HB; Maat P; Aldenhoven M; Algra A; van Gijn J
    J Neurol; 2008 Oct; 255(10):1545-8. PubMed ID: 18769860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Voice Use in Daily Life Studied With a Portable Voice Accumulator in Individuals With Parkinson's Disease and Matched Healthy Controls.
    Gustafsson JK; Södersten M; Ternström S; Schalling E
    J Speech Lang Hear Res; 2019 Dec; 62(12):4324-4334. PubMed ID: 31830844
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A preliminary study of factors influencing perception of articulatory rate in Parkinson disease.
    Tjaden K
    J Speech Lang Hear Res; 2000 Aug; 43(4):997-1010. PubMed ID: 11386485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Speech dysfunction in early Parkinson's disease.
    Stewart C; Winfield L; Hunt A; Bressman SB; Fahn S; Blitzer A; Brin MF
    Mov Disord; 1995 Sep; 10(5):562-5. PubMed ID: 8552106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach.
    García AM; Arias-Vergara T; C Vasquez-Correa J; Nöth E; Schuster M; Welch AE; Bocanegra Y; Baena A; Orozco-Arroyave JR
    Mov Disord; 2021 Dec; 36(12):2862-2873. PubMed ID: 34390508
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Speech therapy for the dysarthria of Parkinson's disease].
    Ozsancak C; Auzou P
    Rev Neurol (Paris); 2005 Sep; 161(8-9):857-61. PubMed ID: 16244572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interobserver reliability and perceptual ratings: more than meets the ear.
    Kearns KP; Simmons NN
    J Speech Hear Res; 1988 Mar; 31(1):131-6. PubMed ID: 3352250
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Change of Vocal Tract Length in People with Parkinson's Disease.
    Pah ND; Motin MA; Oliveira GC; Kumar DK
    Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-4. PubMed ID: 38082914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characteristics of diadochokinesis in multiple sclerosis and Parkinson's disease.
    Tjaden K; Watling E
    Folia Phoniatr Logop; 2003; 55(5):241-59. PubMed ID: 12931058
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The application of dysarthria profile tests in ALS patients for the detection of speech disturbances].
    Tomik B; Głodzik-Sobańska L; Lechwacka A; Bała-Słodowska M; Kolasa M; Szczudlik A
    Neurol Neurochir Pol; 2000; 34(2):269-79. PubMed ID: 10962720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Speech and language therapy treatment on hypokinetic dysarthria in Parkinson disease: Systematic review and meta-analysis.
    Muñoz-Vigueras N; Prados-Román E; Valenza MC; Granados-Santiago M; Cabrera-Martos I; Rodríguez-Torres J; Torres-Sánchez I
    Clin Rehabil; 2021 May; 35(5):639-655. PubMed ID: 33233932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perceptual and instrumental assessments of orofacial muscle tone in dysarthric and normal speakers.
    Dietsch AM; Solomon NP; Sharkey LA; Duffy JR; Strand EA; Clark HM
    J Rehabil Res Dev; 2014; 51(7):1127-42. PubMed ID: 25437151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Articulatory movements during vowels in speakers with dysarthria and healthy controls.
    Yunusova Y; Weismer G; Westbury JR; Lindstrom MJ
    J Speech Lang Hear Res; 2008 Jun; 51(3):596-611. PubMed ID: 18506038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The interpretation of dysprosody in patients with Parkinson's disease.
    Caekebeke JF; Jennekens-Schinkel A; van der Linden ME; Buruma OJ; Roos RA
    J Neurol Neurosurg Psychiatry; 1991 Feb; 54(2):145-8. PubMed ID: 2019840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitative assessment of interutterance stability: application to dysarthria.
    Cummins F; Lowit A; van Brenk F
    J Speech Lang Hear Res; 2014 Feb; 57(1):81-9. PubMed ID: 24687469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.